BioticsAI has received FDA clearance for its ultrasound AI copilot designed to detect fetal abnormalities, marking a transition from development to hospital deployment after operating within a highly regulated healthcare environment.
Startup Focuses On High-Stakes Diagnostic Accuracy
Co-founder and CEO Robhy Bustami said the company is addressing diagnostic challenges in prenatal care, where misdiagnosis rates remain high. The AI system is built to assist clinicians during ultrasound procedures by identifying potential abnormalities.
Bustami discussed the company’s approach during a conversation with Isabelle Johannessen, highlighting the complexity of building healthcare technology where timelines are longer and regulatory requirements shape development.
Early Prototype Built With Limited Resources
BioticsAI developed an initial working version of its product for under $100,000, a relatively low cost compared to typical medical device development. The prototype helped the company gain early recognition, including winning TechCrunch Startup Battlefield 2023.
The early visibility contributed to credibility as the company advanced toward regulatory approval.
Integrated Development Strategy Aligns With FDA Requirements
From the outset, the company combined product development with regulatory planning and clinical validation. This included working with clinicians, collecting datasets, and conducting structured clinical studies before submitting for approval.
Bustami said early engagement with regulators through pre-submission meetings helped clarify expectations and align study design with requirements from the U.S. Food and Drug Administration.
Regulatory Uncertainty Remains A Key Consideration
Despite preparation, regulatory outcomes remain uncertain. Bustami noted that investor concerns often focus on the possibility of rejection during the FDA review process, which can affect timelines and funding decisions.
Team Alignment Supports Long Development Cycles
The company addressed internal challenges tied to extended timelines by maintaining alignment across engineering, clinical, and research teams. Bustami said ensuring visibility into ongoing progress, including clinical study results and partnerships, helped sustain motivation during development.
Deployment Begins Following Approval
With FDA clearance secured in January, BioticsAI has begun deploying its technology in hospitals. The company plans to expand beyond obstetrics into broader reproductive health applications as it scales its product.
Featured image credits: westernimaging.com.au
For more stories like it, click the +Follow button at the top of this page to follow us.